Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 2/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.40 |
| ▸ | AQP1 | P29972 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216283 | 1.00 | PRKAB2 (0.40) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3202664 | 1.00 | PRKAB2 (0.40) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3205932 | 0.87 | AQP1 (0.41) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3207129 | 0.87 | AQP1 (0.41) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3222059 | 0.87 | AQP1 (0.41) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3218119 | 0.87 | PRKAB2 (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3211687 | 0.87 | PRKAB2 (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3203181 | 0.87 | PRKAB2 (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3203448 | 0.85 | AQP1 (0.40) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3203592 | 0.85 | AQP1 (0.40) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH | 2010-02-11 | — | — | US | claimed |
| WO-2008052075-A2 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | claimed |
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH | 2010-02-11 | — | — | US | disclosed |
| WO-2008052075-A2 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | HTR2C, HTR5A, NPY1R | PRKAB2 2961/4885PRKAG1 2626/4885PRKAA2 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.